Abstract: Disclosed embodiments include portable devices for cold chain storage and methods of fabricating portable devices for cold chain storage. In an illustrative embodiment, a portable device for cold chain storage includes a container defining therein a storage region. The container includes an inner cylinder, and the storage region is defined coaxially inwardly of the inner cylinder. The inner cylinder includes phase change material disposed therein, and the phase change material is in thermal communication with the storage region. The inner cylinder also includes evaporative coils disposed therein. The evaporative coils are embedded in the phase change material. The container also includes a thermally insulated outer cylinder. An outer wall of the outer cylinder is disposed radially outwardly of an outer wall of the inner cylinder.

Abstract: An ampoule for a medical liquid, comprising an ampoule body for receiving a medical liquid and a connection part for connecting a removal device to the ampoule. The ampoule body is produced as a plastic injection-molded part by means of a plastic injection molding process. In this manner an ampoule is provided which allows a simple and inexpensive production of the ampoule and can ensure a sterile storage of medical liquids.

Abstract: Dual vial adapter assemblage modified including a drug vial adapter having a female connector fitted with a normally closed needlefree swabable self-sealing access valve, a liquid vial adapter with a male connector and a manually operable flow control arrangement. The flow control arrangement has three operative positions including an initial extended set-up position, an intermediate compacted flow communication position and a final detachment position for separating the drug vial adapter and the liquid vial adapter. The liquid vial adapter and the drug vial adapter are engaged in the initial extended set-up position and the intermediate compacted flow communication position. The self-sealing access valve is closed in the initial extended set-up position and compressed open in the intermediate compacted flow communication position.

Abstract: Disclosed is a method for shortening the drying time for drying an encapsulated material including a coating material containing water without causing deformation of the coating when drying. The method employs a fluidized bed dryer for drying coating materials that contain water and that form a coating when the water evaporates. A first drying step involves floating and fluidizing the encapsulated material and limiting a theorisable evaporating water content ?W so that dimples or deformation do not occur in the coating of the encapsulated granular material while measuring a water content or temperature of gas exhausted from the fluidized bed dryer; and a second drying step, performed after the measure water content is reduced below a prescribed amount or the measured temperature has increased, of blowing in gas to the fluidized bed dryer so that the theorisable evaporating water content ?W rises above that during the first drying step.

Abstract: A device for cutting a medicine tablet includes a base extending along an axis, a cutting device having a fixed cutter and a movable cutter base, and a carrying plate movably disposed inside the base and having a carrying face for a medicine tablet. The fixed cutter is fixedly disposed inside the base, the movable cutter base is optionally positionably moves between protruding and retreating positions axially, the movable cutter base has a movable cutter, when the movable cutter is in the protruding position, a blade of the movable cutter is near a blade of the fixed cutter, and when the movable cutter base is in the retreating position, the blade of the movable cutter is remote from the blade of the fixed cutter. The carrying face faces the blade of the fixed cutter and is able to approach the blade of the fixed cutter.

Abstract: A method for filling a tray with individual medicine portions, which are removed from medicament packs that are provided from an automated storage system by means of an output/input station, is provided. A target filling of accommodating compartments of the tray is provided to a control device, which determines the medicament packs to be removed from storage and the sequence of the removal. For removal, a medicament pack is placed on a first transfer position of the output/input station by an operating device, transported to an output position by a first transport device as soon as the output position is free, and removed from the output position. Individual portions are removed from the medicament pack and introduced into respective accommodating compartments of the tray as indicated by an indicating device. The medicament pack is transported to a second transfer position by a second transport device.

Abstract: Dental composition comprising (a) at least two di- or polyepoxides having 2 to 5 epoxide groups and having a molecular weight of from 200 to 700 Da, or a macromonomeric reaction product obtainable by reacting the diepoxide with a dicarboxylic acid in a molar ratio [diepoxide]/[dicarboxylic acid] of at least 2; (b) one or more primary monoamines and/or disecondary diamines; (c) optionally one or more aliphatic polyamines; (d) a particulate filler, wherein the molar ratio of epoxide groups in component (a) to the N—H bonds in component (b) and (c) [epoxide(a)]/[N—H(b),(c)] is in the range of from 0.9 to 1.

Abstract: A method of cosmetically modifying the appearance of the outline of the eye, the method including the step consisting in applying at least one patch on the movable upper eyelid, the application face of the patch having a predefined non-plane shape with multi-directional curvature, or at least one patch made of a material suitable for responding to stress by deforming in non-elastic manner as to take up multi-directional curvature on the eyelid and conserve the curvature when the stress ceases.

Abstract: The present invention relates to composite powder having enhanced water repellency and oil absorbency by means of even impregnation of inorganic powder particles with a super-water-repellent porous polymer. The composite powder prepared by means of a one-step spraying procedure of electro-spraying or spray drying, according to the present invention, shows super water repellency and maximized oil absorbency by means of increased porosity of porous polymethyl methacrylate (PMMA) and even impregnation with titanium dioxide (TiO2) nanoparticles.

Abstract: The present invention relates to calcium carbonate particles, a powder mixture including such particles and a tooth cleaning method wherein the particles or powder mixture are used.

Abstract: The present invention provides a composition comprising a high load of metal oxides that is phase stable and sprayable. It comprises a branched hydrophobically modified ethoxylated urethane copolymer and a hydrophobically modified alkali swellable emulsion copolymer comprising of one or more acrylate monomers and an ethoxylated associative comonomer.

Abstract: An oral care composition comprising zinc phosphate, stannous fluoride and an organic acid buffer system, as well as methods of using the same.

Abstract: A hair care formulation comprises a diester of a C8-C26 Guerbet alcohol and a C4-C40 dicarboxylic acid. The diester can function as an active ingredient, particularly as a conditioning agent, especially on dry hair. Silicone-free hair care compositions can be produced with effective conditioning properties on both wet and dry hair.

Abstract: The present invention relates to compositions comprising salt of acyl glutamate as primary surfactant or primary anionic surfactant and which further comprise specific preservative systems.

Abstract: The present invention relates to a composition for pharmaceutical, nutritional or cosmetic use, suitable to preserve the physiological condition and health of skin and hair and to reestablish their regenerative functions, characterized in that it comprises a mixture of carnitine, caffeine and arginine as active principle, as such or as derivatives, such as pharmacologically acceptable salts. The effect of preserving the physiologic condition and health of skin and hair, and of reestablishing their regenerative functions is mainly achieved through an increase in ATP production by skin and hair cells.

Abstract: Compositions including a discontinuous oil phase homogeneously dispersed in a continuous water phase, the oil phase containing a sunscreen agent that includes a polymer composition containing a linear, ultraviolet radiation absorbing polyether, the linear, ultraviolet radiation absorbing polyether including a chemically bound UV-chromophore; and an oil-in water emulsifier component including an anionic oil-in-water emulsifier in an amount such that the composition includes about 0.5 percent by weight to about 3 percent by weight of the anionic oil-in-water emulsifier.

Abstract: The invention relates generally to cyclic peptides and their use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said cyclic peptides.

Abstract: Provided herein are microalgal polysaccharide compositions and. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.

Abstract: An oil-based eyelash cosmetic including 22 to 50% by mass of a wax (A) containing a wax having a melting point of 50° C. to less than 70° C. (A-1) and a wax having a melting point of 70° C. to 110° C. (A-2), 0.1 to 10% by mass of a nonionic surfactant having an HLB value of 6 to 12 (B), 20 to 70% by mass of a volatile oil (C) and 0 to 5% by mass of water (E), and having the ratio by mass of the component (A-1) to the component (A-2) [(A-1)/(A-2)] of 1/0.2 to 1/5, is excellent in removability by warm water as well as volume effect, curling effect and long-lasting performance of cosmetic effect such as water resistance.

Abstract: Inventive embodiments disclosed herein includes a cosmetic formulation. The formulation includes an extract that includes a barley grass exposed to light, the extract having a molecular oxygen partial pressure of at least about 180 mbar and a chlorophyll concentration of about 180 mg/kg.

Abstract: A hair strengthening, nourishment, and growth composition and method of application that can be used in the form of a shampoo, conditioner, and a serum.

Abstract: Biodegradable implants comprising dopamine modulating compounds are described.

Abstract: Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.

Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.

Abstract: A drug delivery implant and a method of using the same are disclosed herein. In one or more embodiments, the method includes forming a pocket in the cornea of the eye to gain access to tissue surrounding the pocket; applying a photosensitizer inside the pocket so the photosensitizer permeates at least a portion of the tissue surrounding the pocket and facilitates cross-linking of the tissue surrounding the pocket; irradiating the cornea to activate cross-linkers in the portion of the tissue surrounding the pocket, and thereby stiffen a wall of the pocket and kill cells in the portion of the tissue surrounding the pocket; and before or after the portion of the tissue surrounding the pocket has been stiffened and is devoid of cellular elements by the activation of the cross-linkers, inserting a corneal drug delivery implant into the pocket configured to release one or more medications into the eye.

Abstract: A retaining system for a solenoid assembly of a liquid adhesive dispensing system includes a quick-release mechanism configured to secure the solenoid assembly in place. The quick-release mechanism engages an air tube of the solenoid and thereby secures the entire solenoid assembly to a manifold. The quick-release mechanism can release the solenoid, facilitating easy removal of the entire solenoid assembly, by a simple turning, pushing, or pulling action on the quick-release mechanism. The released solenoid can then be removed and replaced, thereby minimizing downtime caused due to the replacement of a faulty solenoid.

Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: The present invention relates to improved uses of GLP-1 peptides in oral therapy.

Abstract: Described herein is a solid tablet that is directly-compressed of powder, including meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.

Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

Abstract: A preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer is disclosed. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. A stem cell with an enhanced function is disclosed. The stem cell takes up and contains the statin-encapsulated nanoparticle.

Abstract: Systems and methods for coating a particle core with a layer-by-layer film are disclosed.

Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.

Abstract: Disclosed herein are compounds and compositions thereof which find use in increasing stability of TTR tetramers reducing its tendency to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of TTR and thereby decreasing aggegate formation by TTR. Also disclosed herein are methods to screen for candidate compounds that increase stability of TTR. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPis of a target protein.

Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.

Abstract: The present invention relates to a compound for inhibiting thymic stromal lymphopoietin (TSLP) secretion from mast cells and use thereof. The compound of the present invention was confirmed to significantly inhibit TSLP secretion from mast cells and, accordingly, may be used as a candidate compound for treating and preventing atopic dermatitis, allergic dermatitis, and/or inflammatory bowel disease.

Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.

Abstract: The invention relates to a lipid composition comprising fatty acids mainly in the form of triacylglycerols, in which composition at least 50% of the fatty acids are 14-methyl pentadecanoic acids, and at least 8% of the fatty acids are 12-methyl tetradecanoic acids, the percentages being expressed by weight with respect to the total fatty acids of the composition.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.

Abstract: The present disclosure provides methods of treating pulmonary arterial hypertension (PAH) in a subject in need thereof. Compositions for use in these methods are also provided.

Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof in the treatment of conditions and/or disorders related to hyperglycemia.

Abstract: A method for treating a proliferative disease, disorder, or condition comprising administering a cis-diamine platinum(II) thione complex. A cis-diamine platinum(II) thione complex and compositions containing it.